What is the Medigen Biotechnology Corp. stock price forecast?

Medigen Biotechnology Corp. is currently trading at $33.35. View real-time AI analysis on Alpha Lenz.

What is Medigen Biotechnology Corp. insider trading activity?

View the latest insider trading data for Medigen Biotechnology Corp. on Alpha Lenz.

What is Medigen Biotechnology Corp.'s P/E ratio?

View Medigen Biotechnology Corp.'s valuation metrics on Alpha Lenz.

Medigen Biotechnology Corp.

TWSE · 3176

NT$33.35-0.10(-0.30%)

Ask about Medigen Biotechnology Corp.'s future dividend policy...

Alpha Chat Insight

“Medigen Biotechnology Corp.'s ROE is -6.9%. Explore profitability and growth together.”

Ask for details →

Company Overview

Medigen Biotechnology Corp. is a biotechnology company specializing in the research, development, and commercialization of novel drugs and vaccines. Its primary focus includes nucleic acid testing, cytotherapy, advanced vaccine research, generic pharmaceuticals, aesthetic medicine products, and dietary supplements. Medigen Biotechnology Corp. plays a significant role in the health technology sector with a diversified portfolio spanning multiple therapeutic areas, particularly those related to infectious diseases, oncology, and immunotherapy. Headquartered in Taipei and founded in 1999, the company is recognized for its continuous investment in innovation and clinical research, exemplified by developments such as new drug candidates and advanced cell therapies. Medigen Biotechnology Corp. contributes to the advancement of medical science and public health, holding an important position among Taiwan’s major pharmaceutical and medical research enterprises. The company operates through several business segments, reflecting its broad commitment to addressing evolving healthcare needs through scientific advancement and product development.

Websitehttps://www.medigen.com.tw

SectorHealthcare

IndustryBiotechnology

Company Statistics

FY 2025

Profile

N/AMarket Cap

NT$1.58BRevenue

0.00Shares Out

0Employees

Margins

57.19%Gross

-0.96%EBITDA

-6.64%Operating

-13.81%Pre-Tax

-18.70%Net

Valuation

N/AP/E

N/AP/B

N/AEV/Sales

N/AEV/EBITDA

N/AP/FCF

Growth (CAGR)

14.44%Rev 3Yr

20.79%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-4.59%ROA

-6.95%ROE

-3.03%ROIC

Financial Health

NT$1.32BCash & Cash Equivalents

NT$140.95MNet Debt

31.05%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Medigen Biotechnology Corp.'s ROE is -6.9%. Explore profitability and growth together.”

Ask for details →

Frequently Asked Questions

Medigen Biotechnology Corp. (ticker: 3176) is a company listed on TWSE in the Healthcare sector (Biotechnology).

The current price is 33.35 with a P/E ratio of -x and P/B of -x.

ROE is -6.95% and operating margin is -6.64%. Annual revenue is $1.6B.